HSBC upgraded Gilead Sciences Inc. GILD on Monday, citing that the consensus is ‘too pessimistic’ in its assumptions of ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Gilead stock looks like a long-term value buy after the pullback, with HIV growth, Yeztugo sales upside, and a safe dividend.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding ...

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Gilead Sciences is no stranger to making history in HIV. Twelve years after the drugmaker pushed the first pre-exposure prophylaxis (PrEP) HIV med, Truvada, over the FDA finish line, new results from ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment Biktarvy and its new long-acting pre-exposure prophylaxis (PrEP) medicine ...

Shares of Gilead Sciences Inc. GILD slid 1.26% to $129.61 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.72% to 7,537.43 ...

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the ...